A Nomogram Combining Neutrophil-to-Lymphocyte Ratio and D-Dimer Predicts Chemosensitivity of Oxaliplatin-Based First-Line Chemotherapy in Patients with Unresectable Advanced Gastric Cancer

Hao Shen, MMed1,*, Shusheng Wu, MD2,*, Rixin Su, MMed1,*, Yaolin Chen, MMed2, and Yifu He, MD2

Abstract
Introduction: No effective peripheral blood predictors have been established for first-line chemotherapy in patients with advanced gastric cancer. In this study, a nomogram combining the neutrophil-to-lymphocyte ratio/D-dimer with gender, number of metastases, and histological grade was established to predict progression-free survival in patients with unresectable advanced gastric cancer. Methods: We retrospectively collected baseline clinical characteristics and blood parameters from 153 patients diagnosed with advanced gastric cancer that underwent oxaliplatin-based first-line chemotherapy. Kaplan–Meier analysis and Cox regression analysis were used to determine the factors associated with progression-free survival. The concordance index (C-index) and calibration curve were used to determine the prediction accuracy and discriminative ability of the nomogram as a visual complement to the prognostic score system. Results: Determined by the X-tile software, the optimal cut-off points for the neutrophil-to-lymphocyte ratio and D-dimer were 3.18 and 0.56 mg/L, respectively. Multivariate analysis identified four independent prognostic factors: two or more metastatic organs (HR: 1.562, 95% CI: 1.009-2.418, \(P = .046\)), poor differentiation (HR: 0.308, 95% CI: 0.194-0.487, \(P < .001\)), neutrophil-to-lymphocyte ratio >3.18 (HR: 1.427, 95% CI: 1.024-1.989, \(P = .036\)), and D-dimer >0.56 mg/L (HR: 1.811, 95% CI: 1.183-2.773, \(P = .006\)). Receiver operating characteristic curves showed that the combination of the neutrophil-to-lymphocyte ratio and D-dimer in the prediction model exhibited the highest predictive performance (area under the curve, 0.800). The prognostic nomogram yielded a C-index of 0.800. Decision curve analysis demonstrated that the prognostic nomogram was clinically useful. A nomogram-based risk classification system was also constructed to facilitate risk stratification of advanced gastric cancer for optimal clinical management. Conclusion: We identified the neutrophil-to-lymphocyte ratio and D-dimer level as independent prognostic factors for advanced gastric cancer. The prognostic nomogram combining the neutrophil-to-lymphocyte ratio and D-dimer level can be applied in the individualized prediction of treatment outcome in patients with advanced gastric cancer.

Keywords
advanced gastric cancer, NLR, D-dimer, prognostic factor, prognostic model, first-line chemotherapy

Abbreviations
AGC, advanced gastric cancer; AUC, are under the curve; CI, confidence interval; C-index, concordance index; CR, complete response; DCR, disease control rate; HR, hazard ratio; NLR, neutrophil-to-lymphocyte ratio; OS, overall survival; PD,
Introduction

Gastric cancer remains the third highest cause of death from malignancy worldwide.\textsuperscript{1} In East Asia including Korea, Japan, and China had 478,508 new cases and 373,789 deaths from gastric cancer in 2020.\textsuperscript{2} Due to the insidious onset and lack of specific symptoms in the early stage, most patients in developing countries are diagnosed late and cannot undergo radical surgery. Current treatments for advanced gastric cancer (AGC) include palliative gastrectomy, radiation therapy, chemotherapy, molecular targeted therapy, and immunotherapy. At present, oxaliplatin-based chemotherapy remains the main treatment for locally AGC, tumor recurrences, or metastases.\textsuperscript{4} However, many patients must give up further treatment for economic reasons in less developed areas. Previous studies have shown that some tumor endogenous factors, such as the differentiation status or gene expression, can influence the effectiveness of chemotherapy. However, whether other affordable pre-treatment predictors can better predict progression-free survival (PFS) in patients with unresectable AGC is unclear. Determining these predictors may help optimize clinical strategies.\textsuperscript{5}

Systemic inflammation has been reported to play an important role in the progression of various cancers.\textsuperscript{6–8} Circulating inflammatory cells can release a variety of active biological factors, leading to tumor growth, progression, and metastasis.\textsuperscript{9–11} Furthermore, abnormal blood clotting is common in cancer patients, and their hypercoagulable state is also related to angiogenesis, tumor growth, spread, and metastasis, resulting in a poor prognosis. For this reason, D-dimers have been found to reflect fibrinolysis and activation of the coagulation cascade. For example, studies have shown that D-dimer can be used as a prognostic marker for tumor indications in colorectal,\textsuperscript{12} lung,\textsuperscript{13} liver,\textsuperscript{14} ovary,\textsuperscript{15} and gastric cancer progression.\textsuperscript{16} The platelet count is another widely used marker that can be easily obtained from the parameters of whole blood cells. Such prognostic factors are critical to cancer risk stratification, medical treatment, and clinical research. In addition, increasing evidence demonstrates that the neutrophil-to-lymphocyte ratio (NLR) and platelet count can be used to predict gastric cancer.\textsuperscript{17,18} Moreover, a high NLR and elevated D-dimer levels can independently predict poor prognosis of gastric cancer. However, evidence on the relationship between NLR, D-dimer levels, and the predictive role of these indicators in patients with AGC receiving oxaliplatin-based first-line chemotherapy is lacking.

In this study, we developed a new prognostic score combining the NLR and D-dimer levels and established a nomogram combining multiple inflammatory indicators to find the best parameters for predicting survival and clinical responses to first-line chemotherapy in patients with metastatic gastric cancer.

Materials and Methods

Patients and Eligibility Criteria

Data from all patients diagnosed with AGC at Anhui Provincial Hospital from January 2016 to December 2020 were retrospectively reviewed. The inclusion criteria for study participation were as follows: (1) age ≥18 years; (2) unresectable locally advanced gastric cancer, metastatic gastric cancer, or gastroesophageal junction adenocarcinoma confirmed by histopathology or cytology; (3) first-line chemotherapy of an oxaliplatin-based regimen; (4) relapsed more than six months after the end of adjuvant/neoadjuvant chemotherapy (oxaliplatin combined with fluorouracil) or not at all; (5) at least one evaluable lesion; (6) at least two cycles of nontargeted drugs (such as trastuzumab, etc) in combination with first-line palliative chemotherapy; and (7) underwent at least one efficacy evaluation. According to Norman et al.,\textsuperscript{19} the sample size for multivariable analyses had to be >20 times the number of variables, due to the retrospective nature of the study.

Clinical Data Collection

Clinical data including age, gender, tumor metastasis condition, first-line chemotherapy regimen, and first evaluation result were collected. Blood parameters were recorded before chemotherapy, including the white blood cell count, absolute neutrophil count, absolute lymphocyte count, number of red blood cells, hemoglobin concentration, total platelet count, mean platelet volume, albumin, fibrinogen, D-dimer, serum LDH, serum CEA, and serum CA199 levels. Then, the quantitative values of the NLR, platelet-to-lymphocyte ratio, and SII (total platelet count × absolute neutrophil count / absolute lymphocyte count) were calculated. The chemotherapy regimen was an oxaliplatin-based combination chemotherapy regimen consisting of oxaliplatin, leucovorin, and 5-FU (modified FOLFOX); oxaliplatin and capecitabine (XELOX); or oxaliplatin and S-1 (SOX). The RECIST criteria were used to assess chemotherapy efficacy after two cycles. The disease control rate (DCR) was defined as stable disease (SD), partial response (PR), or complete response (CR). Additionally, PFS was defined as the time from randomization to death or disease progression.

Statistical Analysis

Data were analyzed using SPSS (IBM SPSS 26.0, SPSS Inc), R software (version 3.6.1, http://www.r-project.org), and GraphPad Prism (GraphPad Prism 9.0, USA). Additionally, X-tile version 3.6.1 was applied to determine the optimal
cut-off points. The area under the curve (AUC) was used to assess the diagnostic value of the pre-treatment blood indicators, the Chi-squared test or Fisher’s exact test was used for rate comparison, and Student’s t-test was used for normal distribution data comparison. Univariate and multivariate analyses were performed to identify the independent predictors for PFS, and the rms package was used to generate a nomogram based on the logistic regression model. We used the Harrell consistency index (C-index) to determine the discriminative ability of the nomogram. The C-index is a value between 0.5 and 1.0, where 0.5 represents random probability, and 1.0 represents the perfect ability of the model to correctly predict the result. The calibration curve of the nomogram for estimating the PFS was then built, and decision curve analyses were performed. The total points of each patient were determined using the standard logistic model, and three groups of patients with differing prognostic risks (based on total points) were demarcated using the X-tile program. The Kaplan–Meier method was used to illustrate survival curves, which were compared using the log-rank test with the dichotomized risk group as a factor. Every statistical test was two-sided and statistical significance was set at \( P < .05 \) for all analyses.

**Ethics Approval and Consent to Participate**

This study was approved by the Ethics Committee of Anhui Provincial Hospital. The requirement for informed consent was waived by the ethics committee due to the retrospective nature of the study. Additionally, we de-identified all patient details for this study.

**Results**

**Patient Characteristics**

A total of 153 patients with AGC were included in this study, of which 110 (71.9%) were male and 43 (28.1%) were female. The median age at diagnosis was 61 years (range 29-86 years). Regarding histologic grade, 123 (80.4%) patients had poorly differentiated tumors, while 30 (19.6%) had moderate or well differentiated tumors. Moreover, a total of 27 patients (27.8%) had at least two distant organ metastases. Additionally, 38 (24.8%), 43 (28.1%), and 72 (47.1%) patients underwent chemotherapy with fluorouracil/leucovorin/oxaliplatin (FOLFOX), capecitabine/oxaliplatin (XELOX), and oxaliplatin/S-1 (SOX), respectively. The characteristics of all patients are shown in Table 1. The median values of the pre-treatment NLR and D-dimer levels were 3.84 and 2.09, respectively.

**Cut-off Value for NLR and D-Dimer Level**

According to the mean PFS value (5.87 ± 4.55 months), the optimal cut-off value for the NLR and D-dimer level was analyzed using X-tile software (survival time cut-off for PFS at six months). The optimal cut-off value of the NLR was calculated to be 3.18 and the D-dimer level was calculated as 0.56 ug/mL. Thus, patients were classified as high NLR (NLR >3.18) \( (n = 81) \), low NLR (NLR ≤ 3.18) \( (n = 122) \), high D-dimer (D-dimer > 0.58 ug/mL) \( (n = 31) \) (Figure 1).

**Association Between Baseline Blood Parameters and Clinical Characteristics**

The Chi-squared test demonstrated the difference between the baseline blood parameters and clinical characteristics. Gender, age, chemotherapy regimen, histologic grade, number of distant metastases, and results of the first evaluation showed no difference in blood parameter groups before treatment. However, PFS (≥6 months vs <6 months) among all blood parameter groups showed a significant difference. Moreover, gender differed among the pre-treatment D-dimer groups (Table 2). Finally, the NLR and D-dimer were positively correlated \( (r^2 = 0.17, P < .0001; \text{Figure 1C}) \).

**PFS in Patients with Various Clinical Characteristics and Blood Parameters**

Student’s t-test demonstrated the variation of PFS between different clinical and blood parameter groups. PFS showed no statistical difference in gender, age, or platelet count. However, patients with well or moderate differentiation had longer PFS than those with poor differentiation \( (P = .001) \). Additionally, those with only one distant metastatic organ had longer PFS than those with two or more metastatic organs \( (P = .0034) \).
Moreover, the first-time evaluation results showed that the ORR group had longer PFS than the no-ORR group \((P = .0461)\), and the DCR group had longer PFS than the no-DCR group \((P < .0001)\). In the low NLR group \((6.785 \pm 5.332 \text{ months})\), PFS was longer than in the high NLR group \((4.840 \pm 3.200 \text{ months})\) \((P = .0064)\); similarly, in the low D-dimer group \((8.105 \pm 4.525 \text{ months})\), PFS was longer than in the high D-dimer group \((5.302 \pm 4.395 \text{ months})\) \((P = .0020)\) (Figure 2).

**Kaplan-Meier Analysis among Blood Parameters**

Kaplan–Meier analysis showed that PFS of the high NLR group was shorter than that of the low NLR group in 153 patients \((P = .0087)\). Additionally, the PFS of patients in the high D-dimer group was shorter than that of those in the low D-dimer group. All survival curves are shown in Figure 3A-E.

**Univariate and Multivariate Analysis of Clinical and Blood Parameters**

To understand the relationship between clinical features and PFS, univariate analysis including gender, age, histologic grade, number of distant metastases, NLR, and D-dimer was performed. The histologic grade, number of distant metastases, NLR, and D-dimer level were risk factors that significantly influenced PFS (Table 3). Then, gender, histologic grade, number of distant metastases, NLR, and D-dimer level were analyzed by multivariate Cox regression analysis. The results of multivariate analysis indicated that gender \((HR: 1.062, 95\% \text{ CI}: 0.721-1.563, P = .761)\), number of distant metastases \((HR: 1.562, 95\% \text{ CI}: 1.009-2.418, P = .046)\), histologic grade \((HR: 0.308, 95\% \text{ CI}: 0.194-0.487, P < .001)\), NLR \((HR: 1.427, 95\% \text{ CI}: 1.024-1.989, P = .036)\), and D-dimer level

---

**Figure 1.** Cut-off values for the pretreatment blood parameters determined by X-tile software. Abbreviations: NLR, neutrophil to lymphocyte ratio (A); D-dimer (B), correlation analysis between NLR and D-dimer (C).
Predictive Efficacy of NLR, D-Dimer Level, and Clinical Prognostic Factors

According to the median survival time (six months), the patients were classified as having good or poor prognosis. Receiver operating characteristic (ROC) curve analysis demonstrated the performance of the NLR for the prediction of prognosis to have a specificity and sensitivity of 66.10% and 56.00%, respectively (AUC = 0.618). The AUC of the D-dimer level was 0.67, with a specificity and sensitivity of 40.35% and 90.48%, respectively. For predicting the prognosis of patients with AGC after chemotherapy, the combined model had the highest AUC (AUC = 0.800, 95% CI: 0.737-0.879) (specificity = 90.1%, sensitivity = 58.1%). The ROC curves are presented in Figure 4A.

Risk Classification System

In addition to the prognostic nomogram, we also established a risk classification system to classify patients as low-, medium-, and high-risk and rate each patient using the nomogram assessment method based on the total number of patients (Table 4). According to the best cut-off value obtained from the X-tile program, a score of 0–121 indicated low-risk, 122–190 indicated intermediate-risk, and 191–246 indicated high-risk. The Kaplan-Meier curves indicated that the risk classification system could accurately identify the prognosis of different risk groups (Figure 3F). Patients of low-risk had the best prognosis (median 8.6 months), while those of high-risk had the
Figure 2. Student’s t-test for progress-free survival (PFS) between different clinical features and blood parameters. (A) Comparison of mean progress-free survival (PFS) between the different clinical feature groups; (B) comparison of mean progress-free survival (PFS) between the different blood parameter groups. Abbreviations: HG-WAM group, patient’s histologic grade is well or moderate; HG-P group, patient’s histologic grade is poor; NODM = 1, patients had a distant organ metastasis; NODM ≥ 2 group, patients had ≥ 2 metastatic organs; ORR group, the first-time evaluation results was CR or PR; No-ORR group, the first-time evaluation results was SD or PD; DCR group, the first-time evaluation results was CR or PR or SD; No-DCR group, the first-time evaluation results was PD; NLR, neutrophil to lymphocyte ratio.

Figure 3. Kaplan–Meier curves demonstrating progress-free survival according to (A) NLR, (B) D-dimer, (C) Gender, (D) NODM, (E) HG, (F) low-, intermediate-, and high-risk patients. Abbreviations: NLR, neutrophil to lymphocyte ratio; NODM, number of distant metastasis; HG, histological grade.
worst prognosis (median 3.4 months), and intermediate-risk patients had a median PFS of 4.7 months.

**Discussion**

Several studies have evaluated the relationship between blood parameters and gastric cancer; however, most have evaluated the results of surgery, radiotherapy, and postoperative chemotherapy.\(^{20–22}\) Thus, the relationship between PFS after therapy for AGC and blood parameters had not been fully evaluated. In this study, we developed a nomogram using laboratory markers of pre-chemotherapy hematology and systemic inflammatory response to improve prognostic prediction in patients with AGC after chemotherapy. A nomogram is a graphical representation of a complex mathematical formula, which is simpler and more advanced than analyzing blood parameters. Our study showed that improved serum D-dimer levels and a higher pre-chemotherapy NLR were independent negative
predictors of PFS. In previous studies, gender, cell differentiation, and distant metastases have been demonstrated to be prognostic factors.23–26

The mechanisms underlying the relationship between NLR preconditioning and prognosis in patients with inoperable gastric cancer receiving systemic therapy are unclear, but many studies provide possible explanations.27–29 In summary, most neutrophils promote tumor progression by suppressing immune activity, while lymphocytes are considered the most important effector cells in immunotherapy. The NLR is calculated by counting the number of circulating neutrophils to lymphocytes, reflecting the balance between the deleterious effects of neutrophils and the beneficial effects of lymphocyte-mediated immunity.30 Nevertheless, more research is needed to examine the underlying mechanism of this connection. For gastric cancer patients receiving systemic therapy, other predictive biomarkers carry prognostic value. For example, a recent study showed that the immune checkpoint score was an independent predictor of PFS. In this study, the immune checkpoint score was more strongly correlated with PFS than the NLR or D-dimer alone.31 In addition, researchers have also recently developed a radiomic signature to predict the prognosis of gastric cancer and the benefits of chemotherapy.32 Many individual biomarkers, such as IFNGR1,33 CD47,34 and CA19935 have also been reported to be related to the prognosis after systemic treatment of gastric cancer. As a simple and functional biomarker, the NLR is easily obtained from routine blood tests and has powerful applicability in clinical practice.

Impaired fibrinolytic and coagulation systems are another hallmark of cancer, as their components can promote proliferation, survival, and angiogenesis of tumor cells.36 In particular, coagulation-related molecules such as fibrinogen and D-dimer play a role in gastric cancer growth and progression, and their levels are thought to predict prognosis, treatment response, and risk of thrombosis.37 Cancer cells express a variety of cytokines and proteins, disrupting normal cell function and the balance of fibrinolysis and anticoagulation, leading to vascular endothelial damage and release of cytokines and agglutinants, which promotes tumor cell migration, invasion, and vascular leakage. Therefore, anticoagulants play an important role in tumor therapy.36 Among the fibrinolytic and coagulation factors in the tumor microenvironment, fibrinogen and D-dimer are the main components involved in the multi-stage development of tumors. In particular, D-dimer, as a stable fibrin degradation product, can indicate abnormalities in fibrinolysis and coagulation, which are prognostic factors in various malignancies, including GC.15,38–40 As mentioned above, cancer patients often experience chronic inflammation and hypercoagulation. A high NLR indicates systemic inflammation, and elevated D-dimer levels are associated with excessive inflammation and abnormal coagulation. Moreover, because this study evaluated five variables, a sample size of 153 would meet the most stringent guidelines. Additionally, in our study, the combined model better predicted survival compared to the model of the NLR or D-dimer alone. Nevertheless, the current study had several limitations. First, based on this particular study population, the cut-off values for the NLR and D-dimer level were 3.18 and 0.58 ug/mL, respectively. Reviewing the literature, cut-off values for biomarkers, rates, and scores differed based on cancer type and study population/region. Therefore, even within a single cancer type, establishing standard cut-offs that are applicable worldwide proves challenging.21,27,41,42 Second, due to the retrospective nature of this study and the lack of external validation, the prognostic relevance of the combined model in AGC patients requires prospective studies in other populations and larger cohorts. Third, blood cell counts can be affected by several factors; however, we limited some potential confounding factors. Finally, the study lacked follow-up information on overall survival, and the application of other survival outcomes may strengthen our findings.

Conclusion

The NLR and D-dimer level have prognostic value for PFS in patients with AGC receiving first-line palliative chemotherapy. The simple prognostic models based on these independent prognostic factors help identify which patients may benefit from first-line palliative chemotherapy and allow for individualized management of patients with AGC.

Acknowledgments

The authors thank all patients who participated in the present study.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Health Commission of Anhui Province Scientific Research Project, Anhui Province Key Research and Development Program Project, Natural Science Foundation of Anhui Province, Hefei Key Common Technology Research and Major Scientific and

| Table 4. Score Assignment and Risk Stratification. |
|-----------------------------------------------|-----------------|
| Features | Category | Score |
| Gender | Male | 0 |
| | Female | 21 |
| Histologic differentiation | Well and moderate | 0 |
| | Poor | 100 |
| Metastasis | 1 | 0 |
| | ≥2 | 36 |
| NLR | ≤3.18 | 0 |
| | >3.18 | 41 |
| D-Dimer | ≤0.56 | 0 |
| | >0.56 | 69 |
| Risk classification | Low-risk | 0-121 |
| | Intermediate-risk | 122-190 |
| | High-risk | 191-246 |
This study was approved by the Ethics Committee of Anhui Provincial Hospital (batch no: 2022-RE-029). The requirement for informed consent was waived by the ethics committee because of the study’s retrospective nature.

**ORCID iDs**

Hao Shen  
https://orcid.org/0000-0003-3368-9185

Rixin Su  
https://orcid.org/0000-0002-4522-1689

**References**

1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2021;71(3):209-249.

2. Arnold M, Abnet CC, Neale RE, et al. Global burden of 5 major types of gastrointestinal cancer. *Gastroenterology*. 2020;159(1):335-349.e15.

3. Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. *Chin Med J (Engl)*. 2021;134(7):783-791.

4. Zhang X, Liang H, Li Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capецитабине in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. *Lancet Oncol*. 2021;22(8):1081-1092.

5. Wagner AD, Syn NL, Moehler M, et al. Chemotherapy for advanced gastric cancer. *Cochrane Database Syst Rev*. 2017;8(8):CD004064.

6. Miller B, Chalfant H, Thomas A, et al. Diabetes, obesity, and inflammation: impact on clinical and radiographic features of breast cancer. *Int J Mol Sci*. 2021;22(5):2757.

7. Chen L, Zeng H, Yang J, et al. Survival and prognostic analysis of preoperative inflammatory markers in patients undergoing surgical resection for laryngeal squamous cell carcinoma. *BMC Cancer*. 2018;18(1):816.

8. Fu X, Li T, Dai Y, Li J. Preoperative systemic inflammation score (SIS) is superior to neutrophil to lymphocyte ratio (NLR) as a predicting indicator in patients with esophageal squamous cell carcinoma. *BMC Cancer*. 2019;19(1):721.

9. Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. *Immunity*. 2019;51(1):27-41.

10. Mantovani A, Barajon I, Garlanda C. IL-1 and IL-1 regulatory pathways in cancer progression and therapy. *Immunol Rev*. 2018;281(1):57-61.

11. Bottazzi B, Riboli E, Mantovani A. Aging, inflammation and cancer. *Semin Immunol*. 2018;40:74-82. doi:10.1016/j.smim.2018.10.011

12. Ding R, Chen Z, He M, Cen H, Liu Z, Su Y. Application value of combined detection of NLR, PNI, D-dimer, CD3(+) T lymphocytes, and CEA in colorectal cancer screening. *Dis Markers*. 2022;2022:7913025. doi:10.1155/2022/7913025

13. Li J, Yan S, Zhang X, et al. Circulating D-dimers increase the risk of mortality and venous thromboembolism in patients with lung cancer: a systematic analysis combined with external validation. *Front Med (Lausanne)*. 2022;9:853941. doi:10.3389/fmed.2022.853941

14. Chen X, Chang Z, Liu Z. D-dimer increase: an unfavorable factor for patients with primary liver cancer treated with TACE. *Cancer Chemother Pharmacol*. 2019;83(4):797-802.

15. Chen W, Zhong S, Shan B, et al. Serum D-dimer, albumin and systemic inflammatory response markers in ovarian clear cell carcinoma and their prognostic implications. *J Ovarian Res*. 2020;13(1):89.

16. Zhang L, Wang Z, Xiao J, et al. Prognostic value of albumin to D-dimer ratio in advanced gastric cancer. *J Oncol*. 2021;2021:9973743. doi:10.1155/2021/9973743

17. Pikula A, Skorzewska M, Pelc Z, et al. Prognostic value of systemic inflammatory response markers in patients undergoing neo-adjuvant chemotherapy and gastrectomy for advanced gastric cancer in the eastern European population. *Cancers (Basel)*. 2022;14(8):1997.

18. Shi H, Wang H, Pan J, Liu Z, Li Z. Comparing prognostic value of preoperative platelet indexes in patients with resectable gastric cancer. *Sci Rep*. 2022;12(1):6480.

19. Norman G, Monteiro S, Salama S. Sample size calculations: should the emperor’s clothes be off the peg or made to measure? *Br Med J*. 2012;345:e5278. doi:10.1136/bmj.e5278

20. Lieto E, Galizia G, Auricchio A, et al. Preoperative neutrophil to lymphocyte ratio and lymphocyte to monocyte ratio are prognostic factors in gastric cancers undergoing surgery. *J Gastrointest Surg*. 2017;21(11):1764-1774.

21. Yamada T, Hayashi T, Inokuchi Y, et al. Impact of the neutrophil-to-lymphocyte ratio on the survival of patients with gastric cancer treated with nivolumab monotherapy. *Target Oncol*. 2020;15(3):317-325.

22. Li Y, Wang WB, Yang L, et al. The combination of body composition conditions and systemic inflammatory markers has prognostic value for patients with gastric cancer treated with adjuvant chemotherapy: a secondary analysis. *Nutrition*. 2022;93:111464. doi:10.1016/j.nut.2021.111464

23. Sun XJ, Ai L, Feng YC. The value of ABO blood group and complete blood count for the prognosis analysis of gastric cancer patients. *Onco Targets Ther*. 2020;13:4627-4633. doi:10.2147/OTT.S248065

24. Xiang R, Rong Y, Ge Y, Song W, Ren J, Fu T. Cell differentiation trajectory predicts patient potential immunotherapy response and prognosis in gastric cancer. *Aging (Albany NY)*. 2021;13(4):5928-5945.

25. Hwang SG, Kim KM, Cheong JH, et al. Impact of pretreatment thrombocytosis on blood-borne metastases and prognosis of gastric cancer. *Eur J Surg Oncol*. 2012;38(7):562-567.

26. Sun Z, Liu H, Yu J, et al. Frequency and prognosis of pulmonary metastases in newly diagnosed gastric cancer. *Front Oncol*. 2019;9:671. doi:10.3389/fonc.2019.00671

27. Lee S, Oh SY, Kim SH, et al. Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric
cancer patients treated with FOLFOX chemotherapy. *BMC Cancer*. 2013;13(1):350.

28. Graziosi L, Marino E, De Angelis V, Rebonato A, Cavazzoni E, Donini A. Prognostic value of preoperative neutrophils to lymphocytes ratio in patients resected for gastric cancer. *Am J Surg*. 2015;209(2):333-337.

29. Sun J, Chen X, Gao P, et al. Can the neutrophil to lymphocyte ratio be used to determine gastric cancer treatment outcomes? A systematic review and meta-analysis. *Dis Markers*. 2016;2016:7862469. doi:10.1155/2016/7862469

30. Howard R, Kanetsky PA, Egan KM. Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer. *Sci Rep*. 2019;9(1):19673.

31. Wang JB, Li P, Liu XL, et al. An immune checkpoint score system for prognostic evaluation and adjuvant chemotherapy selection in gastric cancer. *Nat Commun*. 2020;11(1):6352.

32. Jiang Y, Yuan Q, Lv W, et al. Radiomic signature of (18)F fluorodeoxyglucose PET/CT for prediction of gastric cancer survival and chemotherapeutic benefits. *Theranostics*. 2018;8(21):5915-5928.

33. Wu D, Zhang P, Ma J, et al. Serum biomarker panels for the diagnosis of gastric cancer. *Cancer Med*. 2019;8(4):1576-1583.

34. Shi M, Gu Y, Jin K, et al. CD47 Expression in gastric cancer clinical correlates and association with macrophage infiltration. *Cancer Immunol Immunother*. 2021;70(7):1831-1840.

35. Zhou Q, Lan X, Li N, Yuan D, Zhang J. Analysis of prognostic factors and design of prognosis model for patients with stage IV gastric cancer following first-line palliative chemotherapy. *Cancer Manag Res*. 2020;12:10461-10468. doi:10.2147/CMAR.S263320

36. Kwaan HC, Lindholm PF. Fibrin and fibrinolysis in cancer. *Semin Thromb Hemost*. 2019;45(04):413-422.

37. Repetto O, De Re V. Coagulation and fibrinolysis in gastric cancer. *Ann N Y Acad Sci*. 2017;1404(1):27-48.

38. Watanabe A, Araki K, Harimoto N, et al. D-dimer predicts postoperative recurrence and prognosis in patients with liver metastasis of colorectal cancer. *Int J Clin Oncol*. 2018;23(4):689-697.

39. Deng HY, Zheng X, Jiang R, Wang RL, Zhou J, Qiu XM. Preoperative D-dimer level is an independent prognostic factor for non-small cell lung cancer after surgical resection: a systematic review and meta-analysis. *Ann Transl Med*. 2019;7(16):366.

40. Hara K, Aoyama T, Hayashi T, et al. Postoperative D-dimer elevation affects tumor recurrence and the long-term survival in gastric cancer patients who undergo gastrectomy. *Int J Clin Oncol*. 2020;25(4):584-594.